Key Market Segment:
By Technology
-
Polymerase Chain Reaction
-
Immunohistochemistry
-
In-situ Hybridization
-
Next Generation Gene Sequencing
-
Others
By Indication
-
Cancer
-
Neurological Diseases
-
Infectious Diseases
-
Others
By End-user
-
Pharmaceutical & Biopharmaceutical Companies
-
Reference Laboratories
-
Contract Research Organizations (CROs)
Request for Segment Customization as per your Business Requirement: Segment Customization Request
Regional Coverage
North America
-
US
-
Canada
-
Mexico
Europe
-
Eastern Europe
-
Poland
-
Romania
-
Hungary
-
Turkey
-
Rest of Eastern Europe
-
-
Western Europe
-
Germany
-
France
-
UK
-
Italy
-
Spain
-
Netherlands
-
Switzerland
-
Austria
-
Rest of Western Europe
-
Asia Pacific
-
China
-
India
-
Japan
-
South Korea
-
Vietnam
-
Singapore
-
Australia
-
Rest of Asia Pacific
Middle East & Africa
-
Middle East
-
UAE
-
Egypt
-
Saudi Arabia
-
Qatar
-
Rest of the Middle East
-
-
Africa
-
Nigeria
-
South Africa
-
Rest of Africa
-
Latin America
-
Brazil
-
Argentina
-
Colombia
Request for Country Level Research Report: Country Level Customization Request
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
-
Product Analysis
-
Criss-Cross segment analysis (e.g. Product X Application)
-
Product Matrix which gives a detailed comparison of the product portfolio of each company
-
Geographic Analysis
-
Additional countries in any of the regions
-
Company Information
-
Detailed analysis and profiling of additional market players (Up to five)
Frequently Asked Questions
The Companion Diagnostics Market size was valued at USD 8.57 billion in 2025 and is expected to witness strong growth over the forecast period.
The market is projected to reach USD 26.38 billion by 2035, reflecting substantial expansion driven by precision medicine and targeted therapies.
The market is anticipated to grow at a compound annual growth rate (CAGR) of 11.9% during the forecast period of 2026–2035.
Key growth drivers include the rising adoption of personalized medicine, increasing prevalence of cancer, growing demand for targeted therapies, and advancements in biomarker-based diagnostics.
Companion diagnostics are widely used in oncology, cardiology, neurology, and infectious diseases, with oncology being the dominant segment.